The clinical significance Of Serum Prohibitin In Chronic Myeloid Leukemia Patients on first line tyrosine kinase inhibitors

Abstract

Background: Prohibitin is widely expressed intra-cellular protein that is distributed in various compartments where they exert different biological functions accordingly. Prohibitins has displayed both pro and anti-tumorogensis roles in cancer formation. Depending on the type of cancer and the localization of the prohibitin, studies has shown that it exerts a different biological role. Aim of the study: This study aims to measure the level of prohibitin in Egyptian patients with CML and correlates its level with their response to first line tyrosysine kinase inhibitors treatment, and other prognostic factors in those patients. Patients and methods: Prohibitin level was measured using Enzyme-linked Immunosorbent Assay (ELISA) in 80 chronic myeloid leukemia patients in the chronic phase. They were recruited from the clinical hematology division of internal medicine department, Ain Shams University hospitals. They were matched to 10 healthy volunteers as a control group. All patients and healthy volunteer signed an informed consent for the withdrawal and use of samples for research purposes in accordance with the 18th World Medical Association Assembly (Declaration of Helsinki, 1964) and all its future amendments. Approval of the local ethical committee was obtained. Results: In our study, we have demonstrated that prohibitin levels were significantly elevated in the patient group. It was also significantly elevated in patients with active disease status. Conclusion: These results denote that prohibitin is over expressed in CML patients and they are linked to disease activity.